Evidence mapPaperPMID 40298782Full record

ReviewAntioxidants (Basel, Switzerland)2025

HDL-Cholesterol and Triglycerides Dynamics: Essential Players in Metabolic Syndrome.

Sebastià Alcover, Lisaidy Ramos-Regalado, Gabriela Girón, Natàlia Muñoz-García, Gemma Vilahur

Abstract readReview
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sebastià AlcoverResearch Institute Sant Pau (IR SANT PAU), 08041 Barcelona, Spain.ORCID 0000-0003-3699-1769
Lisaidy Ramos-RegaladoResearch Institute Sant Pau (IR SANT PAU), 08041 Barcelona, Spain.ORCID 0009-0004-3512-8474
Gabriela GirónResearch Institute Sant Pau (IR SANT PAU), 08041 Barcelona, Spain.
Natàlia Muñoz-GarcíaResearch Institute Sant Pau (IR SANT PAU), 08041 Barcelona, Spain.ORCID 0000-0002-2982-8982
Gemma VilahurResearch Institute Sant Pau (IR SANT PAU), 08041 Barcelona, Spain.

Funding

Agencia Estatal de Investigación PID2021-128891OB-I00Agencia Gestión Ayudas Universitarias Investigación: AGAUR 2016PROD00043EU Horizon 2020 PCI2023-143431Fondo Europeo de Desarrollo Regional (FEDER) MCIN/AEI/10.13039/501100011033Generalitat of Catalunya-Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement de la Generalitat 2017SGR1480Unión Europea NextGenerationEU/PRTR PLEC2021-007664
6 · The paper itself

Abstract

Metabolic syndrome (MetS) is a complex cluster of interrelated metabolic disorders that significantly elevate the risk of cardiovascular disease, making it a pressing public health concern worldwide. Among the key features of MetS, dyslipidemia-characterized by altered levels of high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG)-plays a crucial role in the disorder's progression. This review aims to elucidate the intricate interplay between HDL-C and TG within the context of lipid metabolism and cardiovascular health, while also addressing the detrimental impact of various cardiovascular risk factors and associated comorbidities. The dynamics of HDL-C and TG are explored, highlighting their reciprocal relationship and respective contributions to the pathophysiology of MetS. Elevated levels of TGs are consistently associated with reduced concentrations of HDL-C, resulting in a lipid profile that promotes the development of vascular disease. Specifically, as TG levels rise, the protective cardiovascular effects of HDL-C are diminished, leading to the increased accumulation of pro-atherogenic TG-rich lipoproteins and low-density lipoprotein particles within the vascular wall, contributing to the progression of atheromas, which can ultimately result in significant ischemic cardiovascular events. Ultimately, this paper underscores the significance of HDL and TG as essential targets for therapeutic intervention, emphasizing their potential in effectively managing MetS and reducing cardiovascular risk.

Indexed as

antioxidant activityatherosclerosiscardiovascular diseaseHDLinsulin resistancelipid metabolismmetabolic syndromereverse cholesterol transporttriglycerides

Identifiers

PMID40298782
PMCPMC12024175

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.